fareston
orion corporation - toremifen - bryst neoplasmer - endokrine terapi - første linjehormonbehandling af hormonafhængig metastatisk brystkræft hos postmenopausale patienter. fareston anbefales ikke til patienter med østrogen-receptor negative tumorer.
sugammadex mylan
mylan ireland limited - sugammadex sodium - neuromuskulær blokade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex fresenius kabi
fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskulær blokade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex "reddy" 100 mg/ml injektionsvæske, opløsning
reddy holding gmbh - sugammadexnatrium - injektionsvæske, opløsning - 100 mg/ml
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulær blokade - alle andre terapeutiske produkter - tilbagevendelse af neuromuskulær blokade induceret af rocuronium eller vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex "qilu" 100 mg/ml injektionsvæske, opløsning
qilu pharma spain s.l. - sugammadexnatrium - injektionsvæske, opløsning - 100 mg/ml
sugammadex piramal
piramal critical care b.v. - sugammadex sodium - neuromuskulær blokade - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromuskulær blokade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
bridion
merck sharp & dohme b.v. - sugammadex - neuromuskulær blokade - alle andre terapeutiske produkter - tilbagevendelse af neuromuskulær blokade induceret af rocuronium eller vecuronium. for peadiatric befolkning: sugammadex er kun anbefales til rutinemæssig tilbageførsel af rocuronium-induceret blokade i børn og unge.
sugammadex "hameln" 100 mg/ml injektionsvæske, opløsning
hameln pharma gmbh - sugammadexnatrium - injektionsvæske, opløsning - 100 mg/ml